Evidence map›Paper›PMID 39698572›Full record

ArticleTranslational andrology and urology2024

Predicting pathological upstaging after radical nephroureterectomy in patients with upper tract urothelial carcinoma: results from a multicenter cohort study.

Ryotaro Yamaguchi, Hirokazu Kagawa, Kentaro Yoshihara, Shutaro Yamamoto, Shuhei Hara, Keiichiro Miyajima, Yuki Enei, Wataru Fukuokaya, Kosuke Iwatani, Yu Imai and 17 more

Abstract read
In one paragraph

Article in Translational andrology and urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Ryotaro Yamaguchi *Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Hirokazu KagawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Kentaro YoshiharaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shutaro YamamotoDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shuhei HaraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Keiichiro MiyajimaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Yuki EneiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Wataru FukuokayaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Kosuke IwataniDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Yu ImaiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Mahito AtsutaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Keiichiro MoriDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Taro IgarashiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Koichi AikawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Takafumi YanagisawaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shoji KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Kojiro TashiroDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shunsuke TsuzukiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Gen IshiiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Takahiro HiguchiDepartment of Radiology, The Jikei University School of Medicine, Tokyo, Japan.
Shun SatoDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Yuta YamadaDepartment of Urology, University of Tokyo, Tokyo, Japan.
Akira FurutaDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Tatsuya ShimomuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Jun MikiDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Fumihiko Urabe *Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-2599-8183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the availability of advanced imaging technologies, it remains difficult to achieve sufficient staging accuracy to ensure a tailored treatment strategy for patients with upper tract urothelial carcinoma (UTUC). The aim of the study was to identify preoperative risk factors for tumor upstaging in patients with UTUC initially staged as clinical T2 or lower and to analyze these factors separately for renal pelvic cancer and ureteral cancer. Methods: This retrospective study included data from patients with UTUC who underwent nephroureterectomy. Among them, patients who underwent a staging evaluation using computed tomography urography within 90 days before surgery were selected. Various preoperative factors were evaluated, and multivariate logistic regression analyses were conducted to identify predictors of pathological tumor upstaging. Results: The study included 496 patients, of whom 392 were diagnosed with clinical T2 stage or lower. Among these, 125 patients (31.9%) were upstaged to pathological T3 or T4 disease. Multivariate analysis identified positive voided urine cytology [hazard ratio (HR) =2.94, P<0.001] and tumor size ≥30 mm (HR =1.90, P=0.008) as independent predictors of upstaging. Subgroup analysis showed that positive voided urine cytology (HR =2.71, P=0.004) and tumor size ≥30 mm (HR =3.39, P=0.001) were significant risk factors for renal pelvic cancer. In contrast, significant predictors for ureteral cancer included positive voided urine cytology (HR =3.11, P=0.003) and hydronephrosis (HR =2.69, P=0.03). Conclusions: Positive voided urine cytology and larger tumor size were significant predictors of pathological upstaging in patients with UTUC. Differences in the risk factors between renal pelvic and ureteral cancers highlight the need for tailored preoperative evaluations and management strategies. Further studies are required to refine these predictive models and improve clinical decision-making.

Indexed as

clinical stagenephroureterectomyUpper tract urothelial carcinoma (UTUC)upstaging

Identifiers

PMID39698572
PMCPMC11650334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.